{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:55:52Z","timestamp":1782924952847,"version":"3.54.5"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Siemens Healthcare Diagnostics Inc."},{"DOI":"10.13039\/100008792","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Increased neurofilament light chain (NfL) in cerebrospinal fluid and blood indicates recent neuroinflammatory damage and is prognostic of disease worsening (JAMA Neurol 2023;80:1317\u201325). These studies evaluate the analytical performance of the Siemens Healthineers Atellica IM NfL assay, testing serum and plasma, on the Atellica IM analyzer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Detection capability, linearity, dilution recovery, precision, interfering substance testing, specimen equivalence, method comparison studies, and determination of expected values are all described and performed according to CLSI standards.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The limit of blank, detection, and quantitation were 1.5, 2.0, and 3.0 pg\/mL, respectively. The analytical measuring interval was 3.0 to 300.0 pg\/mL with on-board dilutions extending the reportable range to 3000 pg\/mL. Repeatability and within-lab precision ranged from 0.9% to 5.7% CV and 1.5% to 8.6% CV, respectively. No significant interference was detected for biotin or 38 other substances. Serum SST and plasma EDTA samples provided equivalent NfL results. Comparison of the NfL assay across Siemens Healthineers platforms (Atellica IM, ADVIA Centaur XP\/XPT systems) showed strong alignment; the Atellica IM NfL assay also strongly aligns to the early phase certified reference material (Clin Chem Lab Med 2023;61:1245\u201354). Age-specific expected values for healthy adults were provided, with an overall central 95th percentile range of 3.7 to 18.9 pg\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The Siemens Healthineers Atellica IM NfL assay demonstrated strong performance in all categories of assay development and verification; importantly, results from both healthy and multiple sclerosis patients fall within the reportable range. The Atellica IM NfL assay is for in vitro diagnostic use in the quantitative measurement of NfL in human serum and plasma (EDTA) using the Atellica IM analyzer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jalm\/jfag041","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:43:26Z","timestamp":1772714606000},"page":"844-856","source":"Crossref","is-referenced-by-count":0,"title":["Performance Evaluation of an Automated Neurofilament Light Chain Immunoassay"],"prefix":"10.1093","volume":"11","author":[{"given":"Sarmistha","family":"Ray","sequence":"first","affiliation":[{"name":"Department of Research & Development, Siemens Healthcare Diagnostics Inc. , Tarrytown, NY ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Fayyad","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Siemens Healthcare Diagnostics Inc. , Tarrytown, NY ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Lange","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Siemens Healthcare Diagnostics Inc. , Tarrytown, NY ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charbel","family":"Abou-Diwan","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Siemens Healthcare Diagnostics Inc. , Tarrytown, NY ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Kukkaro","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Clinical Development and Biostatistics Neuroscience, Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter A","family":"H\u00e4ring","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Clinical Development and Biostatistics Neuroscience, Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Gee","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Siemens Healthcare Diagnostics Inc. , Tarrytown, NY ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoDell E","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Siemens Healthcare Diagnostics Inc. , Tarrytown, NY ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddine","family":"Merabet","sequence":"additional","affiliation":[{"name":"Department of Research & Development, Siemens Healthcare Diagnostics Inc. , Tarrytown, NY ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"2026070109532782900_jfag041-B1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.conb.2020.02.001","article-title":"Neurofilaments in disease: what do we know?","volume":"61","author":"Gordon","year":"2020","journal-title":"Curr Opin Neurobiol"},{"key":"2026070109532782900_jfag041-B2","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/brain\/awaa098","article-title":"Neurofilaments: neurobiological foundations for biomarker applications","volume":"143","author":"Gafson","year":"2020","journal-title":"Brain"},{"key":"2026070109532782900_jfag041-B3","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40520-020-01554-8","article-title":"The role of neurofilament light chain in frontotemporal dementia: a meta-analysis","volume":"33","author":"Karantali","year":"2021","journal-title":"Aging Clin Exp Res"},{"key":"2026070109532782900_jfag041-B4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol"},{"key":"2026070109532782900_jfag041-B5","doi-asserted-by":"crossref","first-page":"11624","DOI":"10.3390\/ijms241411624","article-title":"Neurofilament-light, a promising biomarker: analytical, metrological and clinical challenges","volume":"24","author":"Coppens","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026070109532782900_jfag041-B6","doi-asserted-by":"crossref","first-page":"104970","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"EBioMedicine"},{"key":"2026070109532782900_jfag041-B7","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of ms disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"key":"2026070109532782900_jfag041-B8","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1177\/1352458519885613","article-title":"Neurofilament light levels are associated with long-term outcomes in multiple sclerosis","volume":"26","author":"Kuhle","year":"2020","journal-title":"Mult Scler"},{"key":"2026070109532782900_jfag041-B9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","article-title":"Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease","volume":"25","author":"Preische","year":"2019","journal-title":"Nat Med"},{"key":"2026070109532782900_jfag041-B10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(20)30137-X","article-title":"Plasma neurofilament light chain in the presenilin 1 e280a autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study","volume":"19","author":"Quiroz","year":"2020","journal-title":"Lancet Neurol"},{"key":"2026070109532782900_jfag041-B11","doi-asserted-by":"crossref","first-page":"689938","DOI":"10.3389\/fnins.2021.689938","article-title":"Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies","volume":"15","author":"Yuan","year":"2021","journal-title":"Front Neurosci"},{"key":"2026070109532782900_jfag041-B12","doi-asserted-by":"crossref","first-page":"935382","DOI":"10.3389\/fneur.2022.935382","article-title":"Development of a highly sensitive neurofilament light chain assay on an automated immunoassay platform","volume":"13","author":"Lee","year":"2022","journal-title":"Front Neurol"},{"key":"2026070109532782900_jfag041-B13","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol"},{"key":"2026070109532782900_jfag041-B14","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1177\/1352458521993066","article-title":"Serum neurofilament light in MS: the first true blood-based biomarker?","volume":"28","author":"Thebault","year":"2022","journal-title":"Mult Scler"},{"key":"2026070109532782900_jfag041-B15","volume-title":"Atellica IM neurofilament light chain (NfL) assay instructions for use [package insert]","year":"2024"},{"key":"2026070109532782900_jfag041-B16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/acn3.51704","article-title":"Associations of sNfL with clinico-radiological measures in a large MS population","volume":"10","author":"Sotirchos","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"2026070109532782900_jfag041-B17","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1177\/13524585251389797","article-title":"Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis","volume":"31","author":"Ziemssen","year":"2025","journal-title":"Mult Scler"},{"key":"2026070109532782900_jfag041-B18","volume-title":"Siemens Healthineers enters into license and supply arrangement with Quanterix for access to neurofilament light (Nf-L) antibodies to develop Nf-L assays","author":"Didner","year":"2019"},{"key":"2026070109532782900_jfag041-B19","volume-title":"ADVIA Centaur neurofilament light chain (NfL) assay instructions for use [package insert]","year":"2024"},{"key":"2026070109532782900_jfag041-B20","volume-title":"Evaluation of detection capability for clinical laboratory measurement procedures","author":"CLSI","year":"2012"},{"key":"2026070109532782900_jfag041-B21","volume-title":"Evaluation of linearity of quantitative measurement procedures","author":"CLSI","year":"2020","edition":"2nd Ed"},{"key":"2026070109532782900_jfag041-B22","volume-title":"Defining, establishing and verifying an extended measuring interval through specimen dilution and spiking","author":"CLSI","year":"2023"},{"key":"2026070109532782900_jfag041-B23","volume-title":"Evaluation of precision of quantitative measurement procedures; approved guideline","author":"CLSI","year":"2019","edition":"3rd Ed"},{"key":"2026070109532782900_jfag041-B24","volume-title":"Interference testing in clinical chemistry","author":"CLSI","year":"2018","edition":"3rd Ed"},{"key":"2026070109532782900_jfag041-B25","volume-title":"Supplemental tables for interference testing in clinical chemistry","author":"CLSI","year":"2018"},{"key":"2026070109532782900_jfag041-B26","volume-title":"Evaluation of stability of in vitro diagnostic reagents; approved guideline","author":"CLSI","year":"2009","edition":"2nd Ed"},{"key":"2026070109532782900_jfag041-B27","volume-title":"Measurement procedure comparison and bias estimation using patient samples","author":"CLSI","year":"2018","edition":"3rd Ed"},{"key":"2026070109532782900_jfag041-B28","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070109532782900_jfag041-B29","volume-title":"Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline","author":"CLSI","year":"2008","edition":"3rd Ed"},{"key":"2026070109532782900_jfag041-B30"},{"key":"2026070109532782900_jfag041-B31","doi-asserted-by":"crossref","first-page":"103159","DOI":"10.1016\/j.msard.2021.103159","article-title":"High-dose biotin for multiple sclerosis: a systematic review and meta-analyses of randomized controlled trials","volume":"55","author":"Espiritu","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"2026070109532782900_jfag041-B32","doi-asserted-by":"crossref","first-page":"119817","DOI":"10.1016\/j.cca.2024.119817","article-title":"Head-to-head comparison of four plasma neurofilament light chain (NfL) immunoassays","volume":"561","author":"Ashrafzadeh-Kian","year":"2024","journal-title":"Clin Chim Acta"},{"key":"2026070109532782900_jfag041-B33","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1515\/cclm-2022-1181","article-title":"Assessing the commutability of candidate reference materials for the harmonization of neurofilament light measurements in blood","volume":"61","author":"Andreasson","year":"2023","journal-title":"Clin Chem Lab Med"},{"key":"2026070109532782900_jfag041-B34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1373\/clinchem.2017.277558","article-title":"IFCC working group recommendations for assessing commutability part 3: using the calibration effectiveness of a reference material","volume":"64","author":"Budd","year":"2018","journal-title":"Clin Chem"},{"key":"2026070109532782900_jfag041-B35","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1373\/clinchem.2017.277525","article-title":"IFCC working group recommendations for assessing commutability part 1: general experimental design","volume":"64","author":"Miller","year":"2018","journal-title":"Clin Chem"},{"key":"2026070109532782900_jfag041-B36","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1373\/clinchem.2017.277541","article-title":"IFCC working group recommendations for assessing commutability part 2: using the difference in bias between a reference material and clinical samples","volume":"64","author":"Nilsson","year":"2018","journal-title":"Clin Chem"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/11\/4\/844\/68126028\/jfag041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/11\/4\/844\/68126028\/jfag041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:28:56Z","timestamp":1782923336000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/11\/4\/844\/8660267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,21]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfag041","relation":{},"ISSN":["2475-7241"],"issn-type":[{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,4,21]]}}}